MedTrace Logo

HHV8 and Solid Organ Transplantation

NCT05081141 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2024-05-07

No results posted yet for this study

Summary

Solid organ transplant candidates will undergo serological screening for HHV8 at time of listing and transplantation.

In the event of a recipient/donor mismatch R-/D+ or in the presence of a seropositive recipient (R+), blood levels of HHV8 DNA will be monitored together with specific IGRA for HHV8.

Conditions

  • HHV8
  • HHV8 Infection
  • HHV8-Related Malignant Neoplasm
  • Kaposi Sarcoma
  • Lung Transplant; Complications
  • Liver Transplant; Complications
  • Kidney Transplant; Complications
  • Castleman Disease

Interventions

DIAGNOSTIC_TEST

Diagnostic test for HHV8 exposure

Venipuncture for blood sampling

Sponsors & Collaborators

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05081141 on ClinicalTrials.gov